In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...

J.P. Morgan analyst David Adlington maintained a Buy rating on Gerresheimer (0NTI – Research Report) today and set a price target of ...

Even in areas of tech that have done better, bosses note that the war is undermining morale and productivity. What is more, ...

DKSH Healthcare Business Unit, a leading partner for healthcare companies seeking to grow their business in Asia and beyond, is excited to announce a series of initiatives across Asia in observance of ...

Cooper’s pricing power and cost optimization efforts are expected to drive margin expansion. Read why I reiterate a Buy ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Combination corticosteroid-antibiotic preparations, such as TobraDex ® (tobramycin 0.3%/dexamethasone 0.1%) (Alcon, Ft. Worth, TX), and Maxitrol ® (dexamethasone, neomycin, and polymyxin B ...

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating ...

As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.

In this article, Ben Hargreaves asks whether there is particular potential for the technologies to revolutionise staff training and reduce costs in pharma manufacturing. Virtual reality (VR ...